Chulani Karunatilake

Dr. Chulani Karunatilake brings more than 30 years of experience in the biopharmaceutical industry as well as Chemistry and Manufacturing Controls (CMC) process and strategy development to Werewolf Therapeutics. Previously, Dr. Karunatilake served as Senior Vice President of Technical Operations for Maverick Therapeutics (acquired by Takeda), where he was responsible for all aspects of CMC.

Prior to Maverick, Dr. Karunatilake was Senior Vice President of Biologics CMC and initially Vice President of Pharmaceutical Development and Manufacturing at Nektar Therapeutics. He has also held numerous leadership positions at Amgen, Chiron/Novartis, Genentech, and Eli Lilly.

Dr. Karunatilake earned his Ph.D. in Chemistry/Biochemistry from the University of Illinois and holds a B.S. in Chemistry from the University of Colombo in Sri Lanka.